NOK 2.47
(-0.72%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 12.9 Million USD | 97.76% |
2022 | 68.96 Million USD | -76.39% |
2021 | 292.03 Million USD | -85.57% |
2020 | 2.02 Billion USD | 0.0% |
2019 | - USD | -100.0% |
2018 | 129 Thousand NOK | -73.47% |
2017 | 486.18 Thousand NOK | 99.95% |
2016 | 243.14 Thousand NOK | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 544 Thousand USD | -34.22% |
2024 Q1 | 8.7 Million USD | -58.98% |
2023 FY | 136.38 Million USD | 97.76% |
2023 Q2 | 53.58 Million USD | 67.28% |
2023 Q3 | 28.93 Million USD | -46.01% |
2023 Q4 | 23.74 Million USD | -17.95% |
2023 Q1 | 32.03 Million USD | 16.87% |
2022 Q2 | 29.4 Million NOK | 364.85% |
2022 FY | 68.96 Million USD | -76.39% |
2022 Q4 | 27.4 Million USD | 323.29% |
2022 Q3 | 6.47 Million NOK | -77.98% |
2022 Q1 | 6.32 Million NOK | -97.66% |
2021 Q4 | 269.88 Million NOK | 2976.22% |
2021 FY | 292.03 Million USD | -85.57% |
2021 Q3 | 8.77 Million NOK | 0.0% |
2020 FY | 2.02 Billion USD | 0.0% |
2019 FY | - USD | -100.0% |
2018 FY | 129 Thousand NOK | -73.47% |
2017 FY | 486.18 Thousand NOK | 99.95% |
2016 FY | 243.14 Thousand NOK | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Arctic Bioscience AS | 33.75 Million NOK | 61.772% |
Aqua Bio Technology ASA | 1.55 Million NOK | -727.209% |
ArcticZymes Technologies ASA | 118.93 Million NOK | 89.152% |
BerGenBio ASA | 354 Thousand NOK | -3544.633% |
Hofseth BioCare ASA | 194.87 Million NOK | 93.379% |
PCI Biotech Holding ASA | 2.99 Million NOK | -331.505% |
Thor Medical ASA | - NOK | -Infinity% |
Ultimovacs ASA | - NOK | -Infinity% |